LPA-Induced Activation of Satellite Glial Cells and Its Modulation by PIPE-791, a novel LPA1 antagonist, in an In Vitro Pain Model

/in , /by

K.I. Lorrain, A. R. Broadhead, D. Bagnol, M. M. Poon, G. Joseph, J.R. Roppe, A. C. Chen, D. S. Lorrain

Presented at SFN 2025

LPA1 receptor binding sites are abundant in multiple sclerosis patient rim lesions associated with TSPO activation and disease progression

/in , /by

D. Bagnol, A. R. Broadhead, C. S. Baccei, K. I. Lorrain, G. C. Edu, K. Stebbins, M. M.
Poon, J. R. Roppe, T. O. Schrader, L. J. Valdez, A. C. Chen, D. S. Lorrain

Presented at SFN 2025

CNS-Penetrant LPA₁ Antagonist PIPE-791 Provides Superior Analgesia Compared to Peripherally-Restricted CTX-343 in a Rat Model of LPA-Induced Osteoarthritis

/in , /by

A. R. Broadhead, C. S. Baccei, D. Bagnol, K. I. Lorrain, G. C. Edu, M. M. Poon, J. R. Roppe, T. O. Schrader, L. J. Valdez, Y. Xiong, A. C. Chen, D. S. Lorrain

Presented at SFN 2025

The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis

/in , /by

Michael Poon, Kym Lorrain, Alexander Broadhead, Karin Stebbins, Didier Bagnol, Geraldine Edu, Gregory Joseph, Christopher Baccei, Jeffrey Roppe, Thomas Schrader, Lino Valdez, Yifeng Xiong, Austin Chen, and Daniel Lorrain

Respiratory Research

©2025 Contineum Therapeutics Terms of Use Privacy Policy Linkedin Linkedin